遠大醫藥(00512.HK)：新型眼藥“貝美前列素滴眼液”獲頒發藥品註冊證書
格隆匯 3 月 3日丨遠大醫藥(00512.HK)發佈公吿，集團自主研發的新型眼藥“貝美前列素滴眼液”(規格：9mg)已獲中國國家藥品監督管理局頒發藥品註冊證書，為該品種在國內首個獲批的仿製藥物。
貝美前列素滴眼液用於降低原發性開角型青光眼(“POAG”)及高眼壓症患者眼壓，是目前市場上治療POAG及高眼壓症患者的首選藥物。按薈萃分析方法所得的資料顯示，目前治療POAG常見的一線藥物前列腺素類(PGA)產品中，貝美前列素較其他品種具有更強的降眼壓療效，中國、歐洲、美國、亞太等國際青光眼治療指南推薦貝美前列素滴眼液為治療POAG單藥治療首選藥物。此外，集團的貝美前列素滴眼液亦在中國大陸申請三項專利，並已全部獲批。
青光眼嚴重威脅人們的視覺健康，是中國第二大致盲眼科疾病。據弗若斯特沙利文統計，2019年中國青光眼病患接近2,000萬，其中開角型青光眼約佔43.1%,預計到2030年將青光眼患者將增長至2,300萬。目前臨牀上主要將青光眼分為原發性開角型青光眼和原發性閉角型青光眼(PACG)。POAG由於臨牀診斷較差，通常在全面眼科檢查中或在不可逆視力喪失風險較高的晚期階段才會被偶然發現。開角型青光眼的診斷和治療市場仍然有很大的空間，患者數量的快速增長加之青光眼患者長期用藥的需求，該領域具有較大的未被滿足的臨牀需求。
集團作為中國最大的眼科藥研發、生產及銷售綜合企業之一，現有產品覆蓋眼表及眼底多種疾病，具有良好的品牌知名度。為持續鞏固和加強集團在眼科領域的優勢地位，集團一直致力於眼科領域創新產品及首仿產品的開發及引進，目前已針對乾眼症、翼狀胬肉等臨牀需求未被滿足的適應症佈局多款創新產品，同時打造護眼生態圈，在眼用器械及耗材方面進行快速開發。作為集團自主研發的新型眼科用藥貝美前列素滴眼液獲批上市，再次驗證了集團在眼科藥品方面的研發實力，同時該產品進一步豐富了眼科板塊的產品線，持續奠定集團在眼科用藥的龍頭企業地位。集團一直高度重視創新產品和先進技術的研發，以患者需求為核心，持續自主研發新型產品，提升產品市場競爭力。集團將進一步增強產品整體成本優勢、技術優勢，為廣大患者提供優質優價的用藥選擇。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
